Tradestie Institutional Equity Comparison Engine

CVM vs ARTV โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ARTV Overall Edge

ARTV Captures Institutional Edge (2โ€“1 Pillars ยท 4โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Artiva Biotherapeutics, Inc. Common Stock (ARTV) driven by superior Momentum & Technical, Options & Structure while CVM counters with relative strength in Valuation. Fundamentally, CVM trades at 23.0x Forward P/E with 0.0% operating margin (-62.7% YoY revenue) versus ARTV at N/M Forward P/E and 0.0% operating margin (-100.0% YoY). In options structure, CVM sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro) against ARTV sits in BREAKDOWN (<1st %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner CVM
CVM 23.0x vs ARTV N/M Fwd P/E
Growth & Margin Winner Tie
Op Margin 0.0% vs 0.0% ยท YoY -62.7% vs -100.0%
Momentum & Technical Winner ARTV
1Y -77.5% vs +16.5% ยท 52W Pos 10% vs 8%
Options & Structure Winner ARTV
BREAKDOWN (N/A IV) vs BREAKDOWN (<1st %ile IV)
CVM NYSE American
Cel-Sci Corporation
Biological Products, (No Disgnostic Substances)
$1.59
+24.22% 1D
Market Cap $20.9M
1M Return -11.17%
1Y Return -77.48%
Forward P/E 23.0x
Unified AI Score
56.6 / 100 HOLD
Tech 60.0 Fund 54.0 Flow 50.0 Mom 60.0
ARTV NASDAQ
Artiva Biotherapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$3.95
-1.5% 1D
Market Cap $195.8M
1M Return -32.48%
1Y Return +16.52%
Forward P/E N/M
Unified AI Score
60.0 / 100 BUY
Tech 76.0 Fund 66.0 Flow 69.0 Mom 55.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: CVM -77.48% ARTV +16.52% Spread: +97.52 pp (ARTV Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period CVM Revenue ARTV Revenue CVM Op. Margin ARTV Op. Margin Margin Edge
FY2011 $0M N/A -1881.0% N/A CVM
FY2012 $0M N/A -6772.3% N/A CVM
FY2013 $0M N/A -12450.1% N/A CVM
FY2014 $0M N/A -9721.4% N/A CVM
FY2023 N/A $30M N/A -93.2% ARTV
FY2024 N/A $0M N/A -26805.6% ARTV

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: CVM (4) vs ARTV (4)
Institutional Metric CVM ARTV Criterion Row Winner
Market Capitalization Scale $20.9M $195.8M Larger Scale ARTV
Trailing P/E Ratio Valuation 23.0x N/M Lower Multiple CVM
Forward P/E Ratio Valuation 23.0x N/M Lower Multiple CVM
Revenue Growth (YoY) Growth -62.7% -100.0% Higher Growth CVM
Operating Margin (TTM) Profitability 0.0% 0.0% Higher Margin Tie
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -252.5% -43.6% Higher ROE ARTV
52-Week Range Position Momentum 10% ($1โ€“$8) 8% ($3โ€“$15) Stronger Trend CVM
Beta / 30D Volatility Risk Regime 0.65ฮฒ ยท 120% Vol 1.71ฮฒ ยท 116% Vol Lower Realized Risk ARTV
Unified Institutional Score Composite Signal 56.6 / 100 (HOLD) 60.0 / 100 (BUY) Higher Composite ARTV

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full CVM vs ARTV Buy Guide
CVM BREAKDOWN
29d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live CVM Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ARTV BREAKDOWN
146d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile <1st %ile
IV Regime Compressed (<25th %ile)
Live ARTV Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither CVM nor ARTV registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.